buy windows xp professional sp2 to click buy powerdirector 8 deluxe here go to to click discount final cut express 4 mac buy adobe indesign cs4 upgrade buy acrobat 6 buy office 2003 enterprise go to to click buy autodesk softimage 2015 online to click buying ms office 2003 purchase filemaker server cost of revit architecture 2011 go to go to buy windows 7 licence cost of microsoft powerpoint purchase 2003 server r2 price of solidworks 2011 go to here go to buy microsoft money 2007 vista go to windows 7 professional oem vs retail quicken deluxe 2011 discount purchase microsoft office 2007 product key to click go to

Germany’s Merck halts supply of cancer drug to Greek hospitals

Mon, Nov 5, 2012

Oral Cancer News


Date: November 3, 2012

German pharmaceuticals firm Merck KGaA is no longer delivering cancer drug Erbitux to Greek hospitals, a spokesman said on Saturday, the latest sign of how an economic and budget crisis is hurting frontline public services.

Drugmakers raised concerns with EU leaders earlier this year over supplies to the euro zone’s crisis-hit southern half and Germany’s Biotest in June was the first to stop shipments to Greece because of unpaid bills.

Publicly-owned hospitals in some countries worst hit by the euro zone debt crisis had been struggling to pay their bills, Merck’s chief financial officer, Matthias Zachert, was quoted as saying by German paper Boersen-Zeitung in an interview on Saturday.

He said however that the only country where Merck had stopped deliveries was Greece.

“It only affects Greece, where we have been faced with many problems. It’s just the one product,” he told the paper.

A spokesman for the company told Reuters that the drug concerned was Erbitux and that ordinary Greeks can still purchase it from pharmacies.

Some countries have taken action to pay bills, such as in Spain, where the government has said it will help hospitals to pay off debts.

“That has improved things, even though the situation should still be regarded as critical for the coming years,” Zachert said.

Erbitux is Merck’s second best-selling prescription drug, bringing in sales of 855 million euros ($1.1 billion) in 2011 from treating bowel cancer and head and neck cancer. ($1 = 0.7785 euros)

This news story was resourced by the Oral Cancer Foundation, and vetted for appropriateness and accuracy.

Print Friendly
Be Sociable, Share!
, , ,

Leave a Reply

You must be logged in to post a comment.